54 results about "Amphetamine use" patented technology

The invention discloses application of lycium barbarum polysaccharide in preparation of a medicine for inhibiting methylamphetamine-induced nerve injury, and relates to the technical field of biological medicines. It is found and proved that lycium barbarum polysaccharide can inhibit methylamphetamine-induced nerve injury, and the effect is remarkable. From the aspect of cell survival, the survival rate of the microglial cells pretreated by the lycium barbarum polysaccharide after METH stimulation is obviously improved. In the molecular mechanism, the lycium barbarum polysaccharide can effectively lower the protein expression level of the METH-induced pyroptosis marker, the content of inflammatory factors IL-1beta and IL-18 can be reduced, and the release of lactic dehydrogenase is reduced. The result shows that the lycium barbarum polysaccharide can alleviate inflammatory response by inhibiting NLRP3 / ASC pathway mediated microglial cell pyroptosis, thereby inhibiting METH-induced nerve injury. The invention provides a new direction for developing METH neurotoxicity intervention medicines.

The invention belongs to the technical field of medicines, and particularly relates to a preparation containing lisdexamphetamine dimesylate and a preparation method of the preparation. The preparation disclosed by the invention is prepared from the following raw materials in percentage: 10.0%-40.0% of lisdexamphetamine dimesylate, 56.2%-87.7% of microcrystalline cellulose, 2.0%-3.0% of croscarmellose sodium and 0.3%-0.8% of magnesium stearate. Wherein the water content of the microcrystalline cellulose is less than or equal to 4.0%. Compared with the existing preparation, the preparation disclosed by the invention is better in stability, the dissolution performance is consistent with that of the existing preparation, the quality and the use safety of the lisdexamphetamine dimesylate medicine can be effectively improved, and the preparation has a very good application prospect.

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

Described are methods for reducing the formation of amphetamine carbamate and amphetacarbamate in transdermal amphetamine compositions, compositions with low levels of amphetacarbamate, and methods using such compositions for transdermal delivery of amphetamine.

The application belongs to the technical field of water treatment, and particularly relates to a new psychoactive substance adsorbent and application thereof. The preparation method of the adsorbent comprises the following steps: (1) mixing and reacting activated shrimp shell biomass and ferroferric oxide nano magnetic material, drying, and pyrolyzing to obtain Fe3O4@BC; (2) mixing and reacting Fe3O4@BC and ZIF-8 to obtain Fe3O4@BC@ZIF-8; and (3) mixing and reacting a eutectic solvent with Fe3O4@BC@ZIF-8 to obtain the new psychoactive substance adsorbent. The adsorbent has strong adsorption capacity for 4-methyl methcathinone, methcathinone, amphetamine, methamphetamine and ephedrine, and the adsorption efficiency can reach 98% for 4-methyl methcathinone in particular.

The invention relates to a polymeric nanomaterial that has specific affinity for MeA (methamphetamine) or AMP (amphetamine-derived synthetic drugs) and can exist at the nanoscale, as well as to the synthesis method thereof.

The present application relates to a kind of drug rapid detection method, equipment and medium based on photonic crystal image, comprising: image pre-processing, to locate the position of photonic crystal in image and cut image, so that only photonic crystal is left in the image after cutting;Extract the color feature vector of the photonic crystal, and carry out dimension reduction processing;The color feature vector after dimension reduction is converted, identified and compared based on support vector machine, and the drug identification of the to-be-measured body fluid is completed.The present application is based on the color difference of different drugs and photonic crystal after reaction, judges what kind of drug, such as amphetamine, pseudoephedrine, chloroephedrine, methylcathinone or methamphetamine, contained in the to-be-measured liquid by comparing with standard spectrum, fast, low cost, mass detection, low equipment cost.

The invention relates to a medicine with drug rehabilitation and relapse prevention effects as well as a preparation method and application thereof, and belongs to the field of medicines. The medicine comprises rotundine and salts and is prepared through a chemical synthesis method, and experiments prove that the medicine preparation has the effects of treating opioid substances including heroin, morphine, dolantin, methadone and the like as well as other psychoactive substances, such as opioid and the like. Independent or addiction formed by cocaine, amphetamine stimulants, wine, smoke, cannabis sativa, sedative and hypnotic drugs and the like has the effects of detoxifying, relieving symptoms, inhibiting psychological craving and reducing relapse rate.

A process for producing a nitrogen-doped peony-shaped molybdenum oxide, comprising the following steps: (1) adding a regulator to a molybdenum-containing solution for reacting, concentrating and thermally treating to obtain a peony-shaped molybdenum oxide; and (2) dissolving the peony-shaped molybdenum oxide in a conditioning agent and adding an amine source for standing, centrifuging, washing, and heat-treating, thereby obtaining the nitrogen-doped peony-shaped molybdenum oxide; wherein the regulator is at least one of the following: nitric acid, ammonium nitrate, sodium persulfate, ammonium persulfate, concentrated sulfuric acid, H2O2, ozone, sodium hypochlorite, wherein in step (2), the conditioning agent is at least one of the following: sodium acetate, ammonium acetate, sodium formate, diaminoethane, sodium oxalate, ammonium benzoate, sodium phenylacetate, sodium propionate, sodium tartrate, sodium citrate, ammonium citrate; and wherein in step (2) the amine source is at least one of the following: aniline, dimethylamine, trimethylamine, benzylamine, phenethylamine, ethylamine, diethylamine, propylamine, phenylenediamine, xylylenediamine, amphetamine.

The application provides a compound composition for preventing and treating motion sickness and a preparation method thereof, the compound composition comprises the following raw materials in parts by weight: dimenhydrinate 2-6 parts, dextroamphetamine 0.2-0.6 parts, ginger 20-50 parts, dried tangerine or orange peel 10-20 parts, privet fruit 8-15 parts, tribulus terrestris 8-15 parts, rhizoma alocasia 5-12 parts, pachystachys jamaicensis 8-15 parts, daya flower 5-10 parts, litsea cubeba 3-8 parts, kaempferia 3-8 parts, ipomoea alba 5-10 parts, menthol 0.5-3 parts; the compound composition of the application realizes the enhancement of the anti-motion effect and the offset of the side effects, and especially significantly reduces the drowsiness caused by dimenhydrinate and the potential risk of excessive nerve excitement of dextroamphetamine.

This invention provides a method for constructing a donor-acceptor type perylene diimide-based porous conjugated polymer probe and detecting methamphetamine and amphetamine solutions. The method synthesizes donor-acceptor type perylene diimide-based porous conjugated polymer probes with different topologies by combining an electron acceptor perylene diimide derivative and an electron donor aggregation-induced emission fluorophore via a succinate coupling reaction. When used for the detection of methamphetamine and amphetamine, this system exhibits a clear ratiometric fluorescence response, with the fluorescence color gradually changing from yellow-green to orange and orange-red, demonstrating a significant ratiometric fluorescence response. It features fast response speed, high detection sensitivity, good selectivity, and no interference from other common structurally and property-similar substances, enabling the differentiation and identification of methamphetamine and amphetamine.

An efficient, economical and continuous process for the preparation of L-lysine-D-amphetamine dimesylate is provided.

The present invention belongs to the field of biomedicine, and discloses the application of eleutheroside B in the preparation of drugs for preventing and / or treating methamphetamine addiction withdrawal. The inventor evaluated the role of eleutheroside B in preventing and treating methamphetamine addiction by investigating the effects of eleutheroside B on methamphetamine-induced conditioned place preference and behavioral sensitization. It was experimentally confirmed that eleutheroside B could reverse methamphetamine-induced conditioned place preference and reduce methamphetamine-induced hyperlocomotor activity, and had an inhibitory effect on the expression of methamphetamine-induced behavioral sensitization in mice, indicating that eleutheroside B could effectively weaken the dependence and craving for methamphetamine, weaken the induced behavioral sensitization effect, and could be used for preventing and treating methamphetamine addiction. The present invention develops a new drug for drug rehabilitation with eleutheroside B as the active ingredient, provides an effective and safe option for the prevention and treatment of methamphetamine addiction, and has good clinical application prospects.

Described herein are methods for quantitatively determining the amount of the amphetamine-related compound identified herein as amphetamine carbamate (amphetammonium-amphetacarbamate) present in a drug-containing polymer matrix comprising amphetamine, and for assessing a drug-containing polymer matrix comprising amphetamine. The methods may comprise converting any amphetacarbamate present into reaction products comprising carbonate, quantifying the amount of carbonate, and quantifying the amphetacarbamate originally present from the quantified amount of carbonate.

It relates to an oral pharmaceutical solution comprising from 1 mg / ml to 40 mg / ml of a pharmaceutical acceptable salt of lisdexamfetamine, water, a buffer and a polysaccharide wherein the pH of the solution is from 5.0 to 8.5, as well as to its preparation process. The oral pharmaceutical solution is useful for treating attention-deficit and hyperactivity disorder.

The present application belongs to the technical field of drug detection method, and particularly relates to a method for detecting drugs in atmospheric environment samples, comprising the following steps: using the adsorption material of a gas sampling instrument to adsorb the drugs in the gas; after the material adsorbs the drugs, using ultrasonic extraction in an organic solvent or a high-temperature heating method to resolve the drugs; and using high-sensitivity mass spectrometry, molecular immunocolloidal gold or fluorescence method to detect the resolved drugs. The detection method can qualitatively and quantitatively detect the drugs in the atmosphere, and is also suitable for detecting the drugs in the exhaled gas of drug users, and contains new psychoactive drugs such as amphetamines, opioids and synthetic cannabis.

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients. In another aspect, tryptamine compositions described herein enhance neuroplasticity by promoting neuronal branching through the formation of neurites (i.e., neurite outgrowth) and neurite elongation (i.e., increasing neurite length).

The invention discloses a method for detecting methylamphetamine based on an EDTA-Cu quantum dot molecular imprinting fluorescent probe. The method comprises the following steps: step 1, synthesizing EDTA-Cu quantum dots; step 2, preparing an EDTA-Cu quantum dot molecular imprinting fluorescent probe; 3, drawing a standard working curve of fluorescence intensity change ratio-phenylamphetamine concentration; and 4, measuring the content of methylamphetamine in the sample. The EDTA-Cu quantum dot molecularly imprinted fluorescent probe prepared by the invention has high selectivity of a molecularly imprinted polymer, simplicity and convenience in operation and high sensitivity of fluorescence detection, can realize specific recognition and quantitative detection of trace methamphetamine in artificial urine, and is suitable for on-site rapid detection of drugs. According to the detection method, the linear detection range of methylamphetamine is 53-371 nM (the correlation coefficient R is equal to 0.9925), and the detection limit is as low as 20.6 nM.

The present invention is directed to chemical compositions of matter, and in particular a MDMA class of analogs having 1,3-benzothiazoles substituted at the 5 and 6-position with a basic or modified side chain.

Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and / or anxiety disorder, each individually or concurrent.

Abstract Disclosed are d-amphetamine compounds and compositions comprising at least one organic acid covalently bound to d-amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed. Abstract

A process for the preparation of L-lysine-D-amphetamine dimesylate.

The present disclosure relates to compositions comprising 3, 4-methylenedioxy methyl amphetamine (MDMA), or a salt thereof, and MDMA, or a pharmaceutically acceptable salt thereof, in combination with N-acylethanolamine, or a pharmaceutically acceptable salt thereof (e.g., a pharmaceutically acceptable salt thereof). The present invention relates to pharmaceutical compositions comprising a combination of N, N '-dihydroxybutyramide ("PEA") and at least one pharmaceutically acceptable carrier and / or excipient and their use in methods of treating post-traumatic stress disorder (PTSD), anxiety and eating disorders by administering the composition in a therapeutically effective amount to a subject in need thereof.